Breast Cancer | Specialty

Dr. O'Shaughnessy Discusses New Developments in Molecular Profiling in Breast Cancer

August 27th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses new developments in molecular profiling in patients with metastatic breast cancer.

Medivation Acquires BioMarin's PARP Inhibitor Talazoparib

August 25th 2015

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for $410 million, with additional milestone and royalty payments of up to $160 million.

Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast Cancer

August 21st 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses how the results of phosphoprotein assays can impact treatment decisions for select patients with advanced breast cancer.

Molecular Imaging May Help Tailor Breast Cancer Therapies

August 13th 2015

Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals.

Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast Cancer

August 13th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.

Dr. Shannon Puhalla on PALOMA-3 Updates

August 13th 2015

Shannon Puhalla, MD Assistant Professor of Medicine, Division of Hematology, University of Pittsburgh, discusses recent updates of the PALOMA-3 trial.

Oncologists Urged to Help Obese Breast Cancer Patients Manage Weight

August 12th 2015

There is clear evidence that obesity at the time of diagnosis of operable breast cancer is associated with an increased risk of distant recurrence, specifically for HR–positive, HER2-negative disease, and oncologists should consider helping patients better manage their weight as part of their treatment plans.

O'Shaughnessy Details Strategies to Strengthen ER Blockade in MBC

August 11th 2015

Combining estrogen receptor blockade with targeted cell-cycle inhibitors increases therapeutic options for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer, contributing to an evolving paradigm that is moving new regimens to the forefront of the treatment timeline.

Dr. Mamounas on Patient Selection for Endocrine Therapy

August 7th 2015

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses which patients with breast cancer are most likely to benefit from endocrine therapy.

Dr. O'Shaughnessy on Phosphoprotein Assays for Treatment Decision-Making for Breast Cancer

August 5th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses what recent research has shown regarding phosphoprotein assays in treatment decision-making for patients with breast cancer.

Dr. Jahanzeb on Overcoming HER2 Resistance in Breast Cancer

August 4th 2015

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami's Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.

Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast Cancer

August 4th 2015

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.

Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer

August 3rd 2015

Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.

Neoadjuvant Pertuzumab Regimen Approved in Europe for HER2-Positive Early Breast Cancer

July 31st 2015

The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.

Dr. Silverstein on Oncoplasty Versus Mastectomy for Patients With Breast Cancer

July 31st 2015

Melvin J. Silverstein, MD, FACS, medical director, Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, Hoag Memorial Hospital Presbyterian, compares oncoplastic surgery with mastectomy for patients with breast cancer.

Dr. Edith Mitchell on Cancer Disparities Among African American Patients

July 29th 2015

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast Cancer

July 29th 2015

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the research that led to the FDA approval of neoadjuvant pertuzumab as part of a combination regimen for patients with HER2-positive breast cancer.

Progress in HER2-Positive Breast Cancer Comes With Successes and Setbacks

July 22nd 2015

Mohammad Jahanzeb, MD, discusses impactful studies and other key issues in HER2-positive breast cancer.

Investigational Targeted Therapies for Breast Cancer

July 21st 2015

PARP Inhibitors in Triple-Negative Breast Cancer

July 21st 2015